UnitedHealth saw a surge in options volume over the last 10 trading daysShares of UnitedHealth Group Inc (NYSE:UNH) are struggling in 2025, down 39.1% year-to-date. Soaring medical costs -- especially within its Medicare Advantage plans -- and the surprise exit of CEO Andrew Witty have weighed heavily on the healthcare giant. But despite the turmoil, options traders are staying active.UNH just reappeared on Senior Quantitative Analyst Rocky White's list of equities with the highest options volume over the p ...

Key Takeaways UNH stock is down 40.4% YTD, underperforming industry peers and the broader market. Mounting headwinds include rising costs, Medicare scrutiny and a CEO change amid a criminal investigation. Despite solid cash flow, UNH faces continued earnings downgrades and reputational damages.UnitedHealth Group Incorporated (UNH) shares have tumbled 25.4% in the past month alone, bringing their year-to-date loss to 40.4%. That’s well below the performance of both the broader industry (-29.2%) and the S&P ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including administering Medicaid benefits, which were affected by a federal pause on eligibility reviews during COVID-19 [3]. - Following the end of the pause in 2023, states resumed redetermining Medicaid eligibility, which led to significant increases in acuity and utilization among Elevance's Medicaid members [5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate [4]. - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, causing a further stock decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - UnitedHealth Group is facing significant scrutiny and legal challenges following allegations of undisclosed payments to nursing homes aimed at reducing hospital transfers, which has led to concerns about patient care and corporate practices [1][3][4]. Group 1: Allegations and Legal Issues - Allegations have emerged that UnitedHealth incentivized nursing facilities to limit hospitalizations among Medicare Advantage enrollees, potentially compromising patient care [3][4]. - The company is currently involved in a securities fraud class action lawsuit, with claims that it improperly denied health coverage to enhance profits, leading to regulatory scrutiny [5][6]. - A significant drop in UnitedHealth's stock price occurred after the company reduced its financial guidance for 2025, attributing it to unexpected increases in care activity within its Medicare Advantage business [6][7]. Group 2: Management and Regulatory Scrutiny - The abrupt departure of CEO Andrew Witty on May 13, 2025, has added to the turmoil within the company, resulting in a more than 10% decline in share price on that day [7]. - Federal authorities are investigating whether UnitedHealth engaged in "upcoding," a practice that could inflate Medicare payments by misrepresenting patient diagnoses [8]. Group 3: Investigations and Responses - Hagens Berman, a law firm, is investigating the securities fraud claims against UnitedHealth and is encouraging investors who have suffered losses to come forward [2][9]. - The firm has raised concerns about the implications of the recent allegations on UnitedHealth's commitment to patient care and transparency [10].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SelectQuote, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Actions and Investigations - SelectQuote is facing a class action lawsuit initiated by Rosen Law Firm, which seeks recovery of investor losses without any out-of-pocket fees for the shareholders [2] - The U.S. Department of Justice has charged SelectQuote in connection with a False Claims Act complaint against three national health insurance companies and three brokers, alleging unlawful kickbacks and discrimination against disabled Americans [3] - The allegations state that from 2016 to at least 2021, SelectQuote's associated insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [3] Group 2: Market Impact - Following the announcement of the charges on May 1, 2025, SelectQuote's stock experienced a significant decline of 19.2% [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 [4] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - Investors in Elevance Health, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its financial guidance and operational costs [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that between April 18, 2024, and October 16, 2024, Elevance Health failed to disclose critical information to investors, including the fact that sicker patients with higher acuity remained on Medicaid after redetermination, leading to increased per-patient costs [3]. - It is claimed that the rise in costs was not adequately reflected in Elevance's rate negotiations with states or in its financial guidance for 2024, resulting in materially misleading statements about the company's business and prospects [3]. Participation Information - Investors who suffered losses in Elevance Health are encouraged to contact the Law Offices of Howard G. Smith before July 11, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email, phone, or the law firm's website for more information regarding their legal rights and the class action [4][5].

UnitedHealth Group Inc. UNH is officially in the technical doghouse. The healthcare titan just plunged to its most oversold level on both the weekly and monthly charts since the 2008 financial crisis, according to Barchart. The stock has cratered 42% year-to-date, and a staggering 30% in just the past month—leaving even the most hardened bulls shell-shocked.Read Also: As UnitedHealth Wipes Out ‘Unthinkable’ $140 Billion In Market Value Since April, Analysts Weigh In On The Road AheadUNH Stock Breaks Down Te ...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...

Core Insights - Dividend Aristocrats are companies that have increased their dividends for at least 25 consecutive years, demonstrating resilience during economic downturns and showing strength amidst trade-war uncertainties [1] - Medtronic (NYSE: MDT) has been identified as a standout company within the healthcare sector, which is projected to reach $1.87 trillion by 2030 [1][4] Company Analysis - Medtronic operates in over 150 countries with a market capitalization of $103.48 billion, focusing on treatments for cardiovascular disease, diabetes, and neurological disorders [8] - The stock of Medtronic has fluctuated within a 52-week range of $75.96 to $96.25, with analysts projecting an upside of 18.79% and a target price exceeding $109 in the next 12 months [9] - Medtronic has a dividend yield of 3.52% and a payout ratio of 76.98%, indicating strong long-term reinvestment potential [11] Sector Overview - The U.S. healthcare sector is immensely profitable, with demand remaining steady regardless of economic cycles, similar to the grocery and consumer staples sector [4][6] - Pharmaceutical giants, health insurers, and medical device manufacturers are seen as promising investments due to the essential nature of healthcare services [4] Comparative Analysis - Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat, having raised its dividend for 53 consecutive years and operating in over 160 countries [11] - UnitedHealth Group (NYSE: UNH), the largest health insurance provider in the U.S., has faced challenges but maintains a strong dividend growth rate of 14.60% per year over the past five years [12][13] - AbbVie (NYSE: ABBV) and Becton Dickinson (NYSE: BDX) are also notable companies in the sector, with AbbVie facing competition and pricing rule changes, while Becton Dickinson has seen its stock outlook downgraded amid performance concerns [14][15]

On the weekly and monthly Relative Strength Index (RSI) charts, UNH has fallen to a level not seen since the 2008 financial crisis, with the metric reading at 27.78. Importantly, an RSI below 30 often signals a stock is oversold and poised for a bounce. The last time UNH hit this level, it rebounded sharply. After weeks of steep losses driven by leadership changes and regulatory pressures, UNH has dropped from about $600 in early April to $295, marking a nearly 30% decline in just a month. As a result, this ...